The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer

• Alessandra Vultaggio,
• Maria Cristina Petrella,
• Federica Tomao,
• Francesca Nencini,
• Valentina Mecheri,
• Andrea Marini,
• Margherita Perlato,
• Emanuele Vivarelli,
• Claudia De Angelis,
• Ilaria Ferrarini,
• Serena Pillozzi,
• Andrea Matucci,
• Lorenzo Antonuzzo

Affiliations

Alessandra Vultaggio

Immunoallergology Unit, Careggi University Hospital, Florence, Italy

Maria Cristina Petrella

Medical Oncology Unit, Careggi University Hospital, Florence, Italy

Federica Tomao

Department of Gynecologic Oncology, European Institute of Oncology (IEO), IRCSS, Milan, Italy

Francesca Nencini

Immunoallergology Unit, Careggi University Hospital, Florence, Italy

Valentina Mecheri

Immunoallergology Unit, Careggi University Hospital, Florence, Italy

Andrea Marini

Medical Oncology Unit, Careggi University Hospital, Florence, Italy

Margherita Perlato

Immunoallergology Unit, Careggi University Hospital, Florence, Italy

Emanuele Vivarelli

Immunoallergology Unit, Careggi University Hospital, Florence, Italy

Claudia De Angelis

Medical Oncology Unit, Careggi University Hospital, Florence, Italy

Ilaria Ferrarini

Medical Oncology Unit, Careggi University Hospital, Florence, Italy

Serena Pillozzi

Medical Oncology Unit, Careggi University Hospital, Florence, Italy

Andrea Matucci

Immunoallergology Unit, Careggi University Hospital, Florence, Italy; Corresponding author at: Immunoallergology Unit, Careggi University Hospital, Florence 50134, Italy.

Lorenzo Antonuzzo

Medical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy